V itamin D deficiency and hyperparathyroidism are associated with cardiovascular disease (CVD) risk.
however, the major difference between these stiffness parameters is that YEM accounts for carotid artery wall thickness in an attempt to separate whether arterial stiffening is solely related to pressure differences or intrinsic changes in the arterial wall. 15, 18, 27 A limited number of studies have evaluated the associations of elevated PTH and low 25(OH)D with increased arterial stiffness; however, these studies are limited by their small sample size and their cross-sectional design. 2, [28] [29] [30] The aim of this study was to explore the relationship between markers of bone-mineral metabolism and changes in arterial stiffness in an ethnically diverse cohort without clinically evident CVD.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Baseline Characteristics
Baseline characteristics are shown in Table 1 . Participants were a mean (SD) of 60.1 (9.4) years old, 54% were female, 39.5% were white, 25.5% were black, 20.5% were Hispanic, and 14.5% were Chinese. The mean annualized 25(OH) D was 26.3 (11.5) ng/mL and was <20 ng/dL in 816 (30%) participants and 20 to 30 ng/mL in 973 (36%) participants. The mean PTH was 43.5 (18.8) pg/dL and was >65 pg/dL in 285 (11%) participants; 86% of subjects graduated from high school and 44% earned <$40000. The average physical activity score was 1665 MET-min/wk. At baseline, the mean DC was 3.1 (1.3)×10 -3 mm Hg −1 , and the mean YEM was 1591 (938) mm Hg.
Cross-Sectional Associations With Arterial Stiffness Measurements
In cross-sectional analyses, continuous 25(OH)D was not associated with stiffness parameters before or after adjustment for CVD risk factors (P>0.1; Tables 2 and 3) . When grouped by category of 25(OH)D concentrations, no significant trend toward increasing stiffness with lower 25(OH)D was observed after adjustment for traditional CVD risk factors (P>0.3; Figure) . The strongest association with increased stiffness at examination 1 was seen in participants with 25(OH)D concentrations <20 ng/mL (lower DC, β=− 
Discussion
In the current analysis, we observed a cross-sectional association of higher PTH concentrations with increased arterial stiffness that was independent of CVD risk factors except baseline SBP. No associations were present for 25-OHD. After nearly a decade of aging, neither baseline PTH nor 25-OHD concentrations were associated with changes in arterial stiffening.
Potentially deleterious effects of vitamin D deficiency on CVD risk have been described and have even led some clinicians to promote vitamin D supplementation for CVD risk reduction. 28, 32 although the longest of these trials only followed subjects for 3 years. 28 Relationships between vitamin D concentrations and CVD end points have been mixed. For example, low vitamin D concentrations have been associated with increased risk of incident coronary heart disease 33 and presence of coronary artery calcium, 34, 35 but not with congestive heart failure or carotid intima-media 
Calcium, mg/dL 9.6 (0.4) 9.6 (0.4) 9.6 (0.4) 9.7 (0.4) 9.6 (0.4) 9.7 (0.4) 9.6 (0.4) 9.6 (0. All values are mean (SD) unless noted otherwise. 25(OH)D indicates serum 25-hyroxyvitamin D; BMI, body mass index; CRP, c-reactive protein; DBP, diastolic blood pressure; DC, distensibility coefficient; EDI, end-diastolic internal; HDL-C, high-density lipoprotein-cholesterol; HTN, hypertension; IFG, impaired fasting glucose; LDL-C, low-density lipoprotein-cholesterol; meds, medication; NA, not applicable; PSI, peak systolic internal; SBP, systolic blood pressure; and YEM, Young's elastic modulus.
thickness. 36 Associations between low circulating vitamin D concentration and CVD risk may also be partly confounded by CVD risk factors such as obesity and inactivity. 37 The only large, long-term randomized controlled trial of vitamin D supplementation showed no change in CVD events during a 7-year period. 38 High PTH concentrations have been associated with poor CVD outcomes 9 in observational studies. 29, 30 In previous cross-sectional analysis among the Multi-Ethnic Study of Atherosclerosis (MESA) participants, higher PTH concentrations were associated with increased blood pressure, higher central aortic pressure, and lower large artery elasticity. 39 PTH levels seem to be more strongly associated with congestive heart failure events than coronary heart disease events. 9 The results of the present study agree with previously reported studies describing cross-sectional associations between elevated PTH and increased carotid stiffness measures; however, the results were blunted when SBP was included in the model. This suggests that the cross-sectional associations between arterial stiffness and PTH may be mediated through blood pressure. It also is possible that the baseline SBP is more collinear with DC and YEM because pulse pressure, which takes blood pressure into account, is a part of the formulae used to calculate these outcome measures. ‡Sixty-seven participants missing data on covariates. §Eighty-three participants missing data on covariates. ║Sixty-two participants missing data on covariates. ¶Seventy-seven participants missing data on covariates. #P<0.01.
Table 3. Cross-Sectional and Longitudinal Associations of Serum 25(OH)D Concentrations and Young's Elastic Modulus
It may be expected that higher PTH concentrations at baseline would lead to more rapid progression of arterial stiffness during a decade of aging; however, we did not observe a longitudinal association between baseline PTH concentrations and progressive arterial stiffening. Because those with the highest PTH levels also were found to have stiffer arteries at baseline, acceleration of stiffness over time may be blunted because there could be less physiological room for progression of the carotid stiffness parameters (ceiling effect). However, when baseline stiffness parameters were included in the models to attempt to account for this discrepancy, still no associations or even consistent trends were observed. Although PTH and vitamin D were not longitudinally associated with changes in YEM and DC, acceleration of stiffness parameters was observed as expected with traditional CVD risk factors, such as advancing age and hypertension. 40 Alternatively, although 25(OH)D has a relatively long circulating half-life (≈3 weeks) and is considered a good biomarker, a single measurement may not fully capture cumulative vitamin D exposure during a 10-year period, resulting in misclassification. It is similar for PTH, which comparatively has a much shorter half-life (2-4 minutes), making it even more subject to misclassification. A single measurement seems adequate for cross-sectional associations but is less useful during a decade of follow-up.
Several limitations of the current study should be considered. First, we imaged the carotid arteries but measured brachial artery blood pressure. Brachial artery pressure is considered to be a surrogate for central aortic pressure, but may overestimate stiffness measurements because brachial measurements can overestimate central pressures, although the Vitamin D and PTH status were defined by baseline concentrations, and the absence of follow-up levels of either hormone poses a challenge to the interpretation of the longitudinal analyses. This potentially is more likely to be an issue with vitamin D because supplementation is common in the general population, and we did not have information concerning vitamin D supplementation during the follow-up period. Also, the race/ethnicity subgroup analyses may be limited by small sample size. Because all participants had ultrasound studies at exams 1 and 5, there may be a survivorship bias. Participants who were followed up to examination 5 were healthier and less likely to have a nonfatal CVD event than the complete MESA cohort, which would likely result in a null bias.
Conclusions
In cross-sectional analyses, we did not observe any independent associations between arterial stiffness measures and vitamin D status. Carotid arterial stiffness was associated with PTH concentrations >65 mg/dL; however, the associations were attenuated by adjustment for SBP. In longitudinal analyses, advancing age and hypertension were associated with progression of arterial stiffness; however, neither baseline PTH nor 25(OH)D was associated with changes in arterial stiffness measures after nearly a decade of follow-up. Elevated PTH is associated with carotid stiffness; however, the causal and temporal inter-relationships of PTH, blood pressure, and carotid stiffness are not entirely clear and warrant further study.
